Bristol Myers Squibb announced a partnership with Anthropic to deploy Claude AI across the company’s global operations, aiming to accelerate drug discovery and development through enterprise-wide AI integration. The collaboration will roll out Claude to research, clinical development, manufacturing, commercial operations, and corporate functions, supporting more than 30,000 employees. BMS said the initiative targets not only chatbot-style use cases but also embedding AI agents into workflows that advance drug development, including drafting trial documentation and supporting regulatory submission work. The agreement signals continued pressure on large biopharma to capture value from internally generated scientific and clinical data by moving from isolated tools to integrated AI layers across end-to-end development processes.